TREATMENT OF CANCER USING A CD33 CHIMERIC ANTIGEN RECEPTOR
First Claim
Patent Images
1. An isolated nucleic acid molecule encoding a chimeric antigen receptor (CAR), wherein the CAR comprises a CD33 binding domain, a transmembrane domain, and an intracellular signaling domain, and wherein said CD33 binding domain comprises:
- (i) a heavy chain complementary determining region 1 (HC CDR1), a heavy chain complementary determining region 2 (HC CDR2), and a heavy chain complementary determining region 3 (HC CDR3) of any CD33 heavy chain binding domain amino acid sequences listed in Table 2 or 9; and
(ii) a light chain complementary determining region 1 (LC CDR1), a light chain complementary determining region 2 (LC CDR2), and a light chain complementary determining region 3 (LC CDR3) of any CD33 heavy chain binding domain amino acid sequences listed in Table 2 or 9.
9 Assignments
0 Petitions
Accused Products
Abstract
The invention provides compositions and methods for treating diseases associated with expression of CD33. The invention also relates to chimeric antigen receptor (CAR) specific to CD33, vectors encoding the same, and recombinant T cells comprising the CD33 CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD33 binding domain.
-
Citations
69 Claims
-
1. An isolated nucleic acid molecule encoding a chimeric antigen receptor (CAR), wherein the CAR comprises a CD33 binding domain, a transmembrane domain, and an intracellular signaling domain, and wherein said CD33 binding domain comprises:
-
(i) a heavy chain complementary determining region 1 (HC CDR1), a heavy chain complementary determining region 2 (HC CDR2), and a heavy chain complementary determining region 3 (HC CDR3) of any CD33 heavy chain binding domain amino acid sequences listed in Table 2 or 9; and (ii) a light chain complementary determining region 1 (LC CDR1), a light chain complementary determining region 2 (LC CDR2), and a light chain complementary determining region 3 (LC CDR3) of any CD33 heavy chain binding domain amino acid sequences listed in Table 2 or 9. - View Dependent Claims (3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 44, 46, 47, 48, 49, 51, 52, 54, 55, 58, 60, 62, 65, 66, 69)
-
-
2. (canceled)
-
11. (canceled)
-
13. (canceled)
-
24. (canceled)
-
25. An isolated chimeric antigen receptor (CAR) polypeptide, wherein the CAR comprises a CD33 binding domain, a transmembrane domain, and an intracellular signaling domain comprising a costimulatory domain and/or a primary signaling domain, and wherein said CD33 binding domain comprises:
-
(i) a heavy chain complementary determining region 1 (HC CDR1), a heavy chain complementary determining region 2 (HC CDR2), and a heavy chain complementary determining region 3 (HC CDR3) of any CD33 heavy chain binding domain amino acid sequence listed in Table 2 or 9; and (ii) a light chain complementary determining region 1 (LC CDR1), a light chain complementary determining region 2 (LC CDR2), and a light chain complementary determining region 3 (LC CDR3) of any CD33 heavy chain binding domain amino acid sequence listed in Table 2 or 9. - View Dependent Claims (27, 29, 31, 32, 33, 34, 35, 37, 38, 39, 40, 43, 67, 68)
-
-
26. (canceled)
-
28. (canceled)
-
30. (canceled)
-
36. (canceled)
-
41-42. -42. (canceled)
-
45. (canceled)
-
50. (canceled)
-
53. (canceled)
-
56-57. -57. (canceled)
-
59. (canceled)
-
61. (canceled)
-
63-64. -64. (canceled)
Specification